IVDR Revision required

Today's vote in the European Parliament on a joint motion for a resolution on the revision of the Medical Devices Regulation and the In Vitro Diagnostics Regulation (IVDR) underlines the need for action. The Association of the Diagnostics Industry (VDGH) welcomes this step and supports the Parliament's calls for a rapid and targeted revision of the IVDR in order to reduce unnecessary bureaucracy, improve security of supply and ensure access to important diagnostic tests for patients in Europe.

The IVDR was introduced to create more safety and transparency in healthcare. However, experience to date shows that many of the extensive requirements are bureaucratically excessive without increasing patient safety, and the regulatory framework causes significant problems for patient care. The industry has done its homework and created the conditions for safe care, yet the current regulations continue to hinder access to urgently needed diagnostic tests for patients, especially in the areas for rare diseases.


"The IVDR places extensive requirements on the marketing of laboratory diagnostics and has led to considerable delays in the market launch of important products," explains Dr. Martin Walger, Managing Director of the VDGH. "Even established and safe products are at risk of becoming unavailable and no longer available to patients." Small and medium-sized enterprises (SMEs) in particular are disadvantaged by the complex regulatory procedures. "A third of all class D products are at risk of disappearing from the market, including vital tests such as HIV tests and blood donation safety diagnostics. This poses a serious threat to patient safety," Walger continued.


The VDGH is therefore campaigning for a fundamental reform of the IVDR. Together with the German Medical Technology Association (BVMed), a white paper has been drawn up that contains concrete proposals for solutions, including the introduction of an accelerated approval procedure ("fast-track") for innovative products and the abolition of the costly five-year recertification process. "We need more transparency, predictability and efficiency in order to strengthen Europe's competitiveness and at the same time ensure patient care in the long term," demands Walger.


The European Commission is now called upon to take concrete steps. The VDGH expects the new Health Commissioner to act immediately and tackle the problems of the IVDR in order to prevent impending bottlenecks in healthcare. Patients and companies in Europe must no longer suffer from unnecessary bureaucracy and inefficient processes.


Further information and the joint white paper from the VDGH and BVMed can be found online at www.vdgh.de/whitepaper.
 

In a nutshell: The Association of the Diagnostics Industry (VDGH)

The Association of the Diagnostics Industry (VDGH) is a trade association representing the interests of more than 100 companies operating in Germany with a total turnover of 5.5 billion euros in 2024. They manufacture examination systems and reagents for the diagnosis of human diseases, which generate a turnover of more than 2.4 billion euros, as well as instruments, reagents, test systems and consumables for research in the life sciences, which generate a turnover of 3.1 billion euros.

www.vdgh.de

Your press contact

Torsten Kiesner

Press and communication

+49 30 200 599-43

This might also interest you